Rapport Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPP research report →
About the company
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity).
- CEO
- Abraham N. Ceesay
- IPO
- 2024
- Employees
- 69
- HQ
- Boston, DE, US
Price Chart
- Market Cap
- $1.42B
- P/E
- -14.99
- P/S
- 71.12
- P/B
- 3.90
- EV/EBITDA
- -11.47
- Div Yield
- 0.00%
- Gross Margin
- 96.26%
- Op Margin
- -611.03%
- Net Margin
- -536.38%
- ROE
- -24.79%
- ROIC
- -25.34%
- Revenue
- $0 · 0.00%
- Net Income
- $-111,483,000 · -42.37%
- EPS
- $-2.86 · 24.34%
- Op Income
- $-125,099,000
- FCF YoY
- -31.02%
- 52W High
- $43.76
- 52W Low
- $11.71
- 50D MA
- $37.26
- 200D MA
- $30.70
- Beta
- 0.95
- Avg Volume
- 356.44K
Get TickerSpark's AI analysis on RAPP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Gault Cheryl | sell | 1,900 |
| Jun 30, 26 | Gault Cheryl | sell | 3,792 |
| Jun 30, 26 | Gault Cheryl | sell | 3,308 |
| Jun 30, 26 | Gault Cheryl | sell | 1,000 |
| Jun 29, 26 | Ceesay Abraham | sell | 7,344 |
| Jun 29, 26 | Ceesay Abraham | sell | 876 |
| Jun 10, 26 | MARAGANORE JOHN | other | 15,200 |
| Jun 10, 26 | PEREZ ROBERT J | other | 15,200 |
| Jun 10, 26 | PAUL STEVEN M | other | 15,200 |
| Jun 10, 26 | Silva Paul M | other | 15,200 |
Our RAPP coverage
Recent articles, reports, and earnings notes.
No research on RAPP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAPP report →Similar companies
Peers in the same neighborhood.